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i.org/1risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal
antibody to proprotein convertase subtilisin/kexin type 9, reduced low-density lipoprotein
cholesterol (LDL-C) by up to 62% from baseline in phase 3 studies, with adverse event rates
similar between alirocumab and controls. We evaluated the effect of alirocumab on serum
Lp(a) using pooled data from the phase 3 ODYSSEY program: 4,915 patients with hy-
percholesterolemia from 10 phase 3 studies were included. Eight studies evaluated alir-
ocumab 75 mg every 2 weeks (Q2W), with possible increase to 150 mg Q2W at week 12
depending on LDL-C at week 8 (75/150 mg Q2W); the other 2 studies evaluated alirocumab
150-mg Q2W from the outset. Comparators were placebo or ezetimibe. Eight studies were
conducted on a background of statins, and 2 studies were carried out with no statins.
Alirocumab was associated with signiﬁcant reductions in Lp(a), regardless of starting dose
and use of concomitant statins. At week 24, reductions from baseline were 23% to 27% with
alirocumab 75/150-mg Q2W and 29% with alirocumab 150-mg Q2W (all comparisons p
<0.0001 vs controls). Reductions were sustained over 78 to 104 weeks. Lp(a) reductions with
alirocumab were independent of race, gender, presence of familial hypercholesterolemia,
baseline Lp(a), and LDL-C concentrations, or use of statins. In conclusion, in addition to
marked reduction in LDL-C, alirocumab leads to a signiﬁcant and sustained lowering of
Lp(a).  2016 The Author(s). Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am
J Cardiol 2017;119:40e46)Alirocumab, a monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 (PCSK9), reduced low-
density lipoprotein cholesterol (LDL-C) levels from base-
line to 24 weeks by up to 62% versus controls in 10 phase 3
studies involving mainly patients at high cardiovascular
(CV) risk, including those with previous CV events and
those with heterozygous familial hypercholesterolemia
(HeFH).1e9 Previously, a pooled analysis of 3 alirocumab
phase 2 studies reported median reductions in lipoprotein (a)
[Lp(a)] of 30% after 8 to 12 weeks of treatment.10 Inf Medicine, ECOGENE-21 Clinical and Translational
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0.1016/j.amjcard.2016.09.010individual phase 3 studies, alirocumab reduced Lp(a) by an
average of 25% to 30% from baseline to week 24 in patients
with HeFH and in non-FH patients.4,8 The aim of the present
analysis was to evaluate the maintenance of the Lp(a)-
lowering effect with alirocumab over 24 to 104 weeks in
a pooled analysis of 10 phase 3 studies (n ¼ 4,915). Po-
tential heterogeneity of treatment effect according to HeFH
status and other baseline characteristics were also examined.Methods
Data from 10 randomized, double-blind, phase 3,
controlled trials were included in this analysis. Efﬁcacy data
were pooled into 4 groups according to alirocumab dose,
comparator, and concomitant statin use (Figure 1). Two
studies used an alirocumab dose of 150 mg every 2 weeks
(Q2W). The other 8 studies started with alirocumab 75-mg
Q2W that was increased to 150-mg Q2W at week 12
depending on achieved LDL-C at week 8 (indicated in the
text as 75/150-mg Q2W). Comparators were placebo or
ezetimibe. In 8 studies, patients received concomitant statin
(with or without other lipid-lowering therapy). The statin was
at maximally tolerated dose in 6 studies (atorvastatin 40 to
80 mg, rosuvastatin 20 to 40 mg, or simvastatin 80 mg daily,
unless an investigator-approved reason was given for using a
lower dose). All study protocols were approved by the rele-
vant institutional review boards or independent ethics com-
mittees, and all patients provided written informed consent.ccess article
4.0/).
www.ajconline.org
Figure 1. Overview of studies included in this analysis. All patients randomized to either ALI, PBO, or EZE were included. Patients randomized to the statin
control arms in OPTIONS I, OPTIONS II, and ALTERNATIVE were not included in this analysis. The ITT population included all randomized patients with a
baseline and at least one postbaseline LDL-C measurement, regardless of treatment adherence. The safety population includes all randomized patients who
received at least one dose or part of a dose of study treatment. Supplementary Table 1 lists the number of patients in the efﬁcacy and safety analysis for the
individual studies. Study references and clinicaltrials.gov identiﬁers: LONG TERM, NCT015078318; HIGH FH, NCT016176555; FH I NCT016231154; FH II,
NCT017095004; COMBO I, NCT016441756; COMBO II, NCT016441882; OPTIONS I, NCT017300401; OPTIONS II, NCT017300533; ALTERNATIVE,
NCT017095137; MONO, NCT01644474.9 †75/150-mg Q2W indicates that the starting dose of 75-mg Q2W could be increased to 150-mg Q2W at week 12, if
LDL-C was above prespeciﬁed levels at week 8. zConcomitant nonstatin LLT apart from ezetimibe allowed in ALTERNATIVE; no concomitant LLT allowed
in MONO. xConcomitant statin at maximally tolerated doses (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, or simvastatin 80 mg; lower doses were
allowed with an investigator-approved reason). kNo concomitant nonstatin LLT allowed in COMBO II. {Concomitant statin and doses were atorvastatin 20 or
40 mg in OPTIONS I and rosuvastatin 10 or 20 mg in OPTIONS II. ALI ¼ alirocumab; EZE ¼ ezetimibe; ITT ¼ intention-to-treat; LLT ¼ lipid-lowering
therapy; PBO ¼ placebo; Q2W ¼ every 2 weeks.
Preventive Cardiology/Alirocumab Effect on Lipoprotein(a) 41Prespeciﬁed end points included percentage change in
Lp(a) and LDL-C from baseline at week 12 (before potential
dose adjustment) and week 24 (and weeks 52 to 104 for
longer trials), analyzed using an intention-to-treat (ITT)
approach that included all data regardless of adherence to
treatment and also using only on-treatment data. Analytical
methods and statistical analysis methods are described in the
Supplementary Material.
Results
Patient numbers included in the analysis are shown in
Figure 1 (further details for individual studies are listed in
Supplementary Table 1). Baseline characteristics, including
median Lp(a) levels, were generally similar between alir-
ocumab and control groups within each of the 4 study pools
(Table 1). There was a higher proportion of men in all
groups (w60%), most patients were white (w90%;
Table 1). Overall, median baseline Lp(a) levels were higher
in patients with HeFH (26.0 mg/dl) versus non-FH
(22.9 mg/dl; p ¼ 0.0004; Supplementary Table 2). Median
baseline Lp(a) levels were lower in studies performed
without concomitant statin versus studies performed with
statin (p <0.0001; Supplementary Table 3). Furthermore, inan analysis of studies for which baseline PCSK9 levels were
available, median baseline levels of free and total PCSK9
were lower in the MONO study (no statin) versus studies
performed with statin (p <0.0001; Supplementary Table 3).
Correlation analyses suggested that higher baseline PCSK9
levels were associated with higher baseline Lp(a) levels
(Supplementary Figure 1). Across the pools, w30% of pa-
tients displayed Lp(a) >50 mg/dl at baseline (Table 1);
baseline characteristics for these patients are listed in
Supplementary Table 4. Baseline Lp(a) and LDL-C levels
for the individual studies are listed in Supplementary
Table 5.
Compared with placebo or ezetimibe, alirocumab
signiﬁcantly reduced Lp(a) and LDL-C from baseline at
both weeks 12 and 24 in each pool (Table 2). Dose increase
from 75 to 150 mg was associated with an additional 7.1%
reduction in Lp(a) across studies performed with statins
(Supplementary Table 6) although no additional effect was
seen in studies performed without statin. Reductions in
Lp(a) were maintained up to end of study in the 78-week
and 104-week studies (Figure 2). Among patients with
baseline Lp(a) 50 to <75 mg/dl, 47.1% to 61.7% of
alirocumab-treated patients across the study pools achieved
Lp(a) <50 mg/dl by week 24 (Supplementary Table 7).
Table 1
Baseline characteristics of all randomized patients in the 10 studies
Placebo-controlled studies Ezetimibe-controlled studies





















Age (years), mean  SD 60.0  10.8 60.2  10.6 55.6  12.9 55.5  12.5 61.6  9.7 62.3  9.7 63.1  8.1 61.9  9.1
Male 1018 (62.6%) 496 (60.3%) 397 (56.8%) 216 (61.4%) 483 (70.4%) 294 (66.2%) 98 (55.1%) 94 (53.4%)
White 1505 (92.6%) 760 (92.3%) 634 (90.7%) 312 (88.6%) 582 (84.8%) 385 (86.7%) 163 (91.6%) 163 (92.6%)
Black 54 (3.3%) 25 (3.0%) 36 (5.2%) 22 (6.3%) 39 (5.7%) 26 (5.9%) 11 (6.2%) 11 (6.3%)
Asian 15 (0.9%) 9 (1.1%) 10 (1.4%) 2 (0.6%) 39 (5.7%) 25 (5.6%) 2 (1.1%) 2 (1.1%)
American Indian or Alaska Native 28 (1.7%) 18 (2.2%) 4 (0.6%) 1 (0.3%) 6 (0.9%) 1 (0.2%) 0 0
Native Hawaiian or Other Paciﬁc
Islander
0 0 0 1 (0.3%) 0 0 1 (0.6%) 0
Other 23 (1.4%) 11 (1.3%) 15 (2.1%) 14 (4.0%) 20 (2.9%) 7 (1.6%) 1 (0.6%) 0
Body mass index, (kg/m2), mean  SD 30.1  5.7 30.5  5.4 30.0  5.5 30.1  6.0 30.3  5.9 30.7  5.6 29.7  6.4 28.4  5.5
Heterozygous familial
hypercholesterolemia
348 (21.4%) 174 (21.1%) 490 (70.1%) 245 (69.6%) 26 (3.8%) 18 (4.1%) 14 (7.9%) 25 (14.2%)
Cardiovascular risk level
Very high 1451 (89.3%) 751 (91.3%) 438 (62.7%) 224 (63.6%) 601 (87.6%) 371 (83.6%) 73 (41.0%) 62 (35.2%)
High 174 (10.7%) 72 (8.7%) 261 (37.3%) 128 (36.4%) 85 (12.4%) 73 (16.4%) 29 (16.3%) 47 (26.7%)
Moderate 0 0 0 0 0 0 71 (39.9%) 65 (36.9%)
Concomitant medication
Maximally tolerated statin 1625 (100.0%) 823 (100.0%) 699 (100.0%) 352 (100.0%) 479 (69.8%) 241 (54.3%) 0 0
High-intensity statin† 744 (45.8%) 367 (44.6%) 527 (75.4%) 266 (75.6%) 421 (61.4%) 260 (58.6%) 0 0
Lipid-lowering therapies other than
statin
450 (27.7%) 225 (27.3%) 375 (53.6%) 205 (58.2%) 51 (7.4%) 41 (9.2%) 43 (24.2%) 48 (27.3%)
Aspirin 1019 (62.7%) 529 (64.3%) 349 (49.9%) 171 (48.6%) 481 (70.1%) 307 (69.1%) 80 (44.9%) 82 (46.6%)
Lipids, mean  SD (mg/dL)
Low-density lipoprotein cholesterol
(Friedewald formula)
125.9  45.9 125.3  44.5 129.0  47.3 130.3  45.4 109.4  35.6 105.0  36.2 176.5  66.8 177.4  66.0
High-density lipoprotein cholesterol 49.8  12.3 49.8  12.4 50.5  15.4 49.7  14.4 48.0  13.2 48.3  13.1 50.5  15.7 53.3  16.3
Non-high-density lipoprotein
cholesterol
155.8  49.4 155.4  48.6 155.5  50.0 155.8  48.4 139.3  39.7 135.4  41.8 211.7  75.1 210.8  77.4
Fasting triglycerides, median
(Q1:Q3)
132.0 (93.8 : 182.3) 134.5 (94.7 : 188.5) 114.0 (85.0 : 161.0) 111.0 (86.0 : 156.0) 129.0 (96.0 : 185.0) 134.0 (97.0 : 187.0) 147.5 (105.0 : 218.0) 130.0 (89.5 : 201.5)
Apolipoprotein B 103.5  28.9 103.3  28.8 106.1  29.3 105.6  27.8 94.3  23.0 92.3  23.5 131.0  38.7 128.6  36.6
Apolipoprotein A-1 146.2  25.1 146.7  27.1 143.7  27.3 142.5  27.1 142.0  23.8 142.7  24.7 150.4  26.3 153.9  27.7
Lipopotein(a), median (Q1:Q3) 22.2 (7.7 : 66.1) 21.5 (6.7 : 66.8) 29.0 (10.0 : 81.0) 26.0 (8.0 : 75.0) 26.0 (8.0 : 74.0) 24.0 (10.0 : 61.0) 17.0 (6.0 : 44.5) 15.0 (7.0 : 39.0)
Distribution of Lipoprotein(a) baseline levels
<30 896 (56.3%) 459 (56.6%) 340 (50.4%) 183 (53.4%) 353 (52.5%) 234 (54.0%) 112 (65.1%) 110 (65.9%)
30 to <50 190 (11.9%) 85 (10.5%) 91 (13.5%) 39 (11.4%) 69 (10.3%) 63 (14.5%) 22 (12.8%) 26 (15.6%)
50 to <75 172 (10.8%) 99 (12.2%) 62 (9.2%) 35 (10.2%) 83 (12.3%) 46 (10.6%) 17 (9.9%) 11 (6.6%)
75 to <100 123 (7.7%) 66 (8.1%) 65 (9.6%) 24 (7.0%) 64 (9.5%) 33 (7.6%) 10 (5.8%) 10 (6.0%)
100 211 (13.3%) 102 (12.6%) 117 (17.3%) 62 (18.1%) 104 (15.5%) 57 (13.2%) 11 (6.4%) 10 (6.0%)
SD ¼ standard deviation.
* 75/150 mg indicates that the starting dose of 75-mg Q2W could be increased to 150-mg Q2W at week 12, if LDL-C had not decreased to predetermined levels at week 8.
















Percentage changes in plasma concentrations of Lp(a) and LDL-C from baseline to weeks 12 and 24 (intent-to-treat population analysis)
Treatment groups Week 12 Week 24
Alirocumab Control Difference alirocumab
vs. control
Alirocumab Control Difference alirocumab
vs. control
Alirocumab 150 mg (n¼1601) vs. placebo (n¼815) with statin
Lipoprotein(a) e28.0  0.7 e3.0  0.9 e25.0  1.2* e29.1  0.7 e4.0  1.0 e25.1  1.2*
Low-density lipoprotein cholesterol e62.6  0.7 1.1  1.0 e63.8  1.2* e60.4  0.7 0.5  1.0 e60.9  1.2*
Alirocumab 75/150 mg† (n¼693) vs. placebo (n¼350) with statin
Lipoprotein(a) e21.7  0.9 e3.2  1.3 e18.5  1.6* e25.0  1.0 e7.7  1.4 e17.4  1.7*
Low-density lipoprotein cholesterol e44.5  1.0 4.1  1.3 e48.6  1.6* e48.6  1.0 4.2  1.5 e52.7  1.8*
Alirocumab 75/150 mg† (n¼669) vs. ezetimibe (n¼436) with statin
Lipoprotein(a) e22.0  1.0 1.5  1.3 e23.5  1.7* e27.1  1.2 e5.3  1.5 e21.8  1.9*
Low-density lipoprotein cholesterol e49.2  1.2 e22.3  1.5 e26.8  1.9* e48.9  1.4 e19.3  1.7 e29.6  2.2*
Alirocumab 75/150 mg† (n¼178) vs. ezetimibe (n¼173) without statin
Lipoprotein(a) e20.1  1.9 e7.3  2.0 e12.9  2.8* e23.3  2.0 e8.9  2.1 e14.4  2.9*
Low-density lipoprotein cholesterol e47.4  1.5 e16.7  1.6 e30.7  2.2* e45.6  1.8 e14.8  1.8 e30.9  2.6*
Data are adjusted mean percentage change  standard error.
* p <0.0001 versus control.
† Dose was increased from 75 to 150 mg at week 12 in 43.9% and 17.7% of patients in the ezetimibe-controlled pools without and with concomitant statin,
respectively, and in 34.2% of patients in the placebo-controlled pool.
Figure 2. Adjusted mean percentage change in plasma Lp(a) concentration from baseline in (A) LONG TERM and HIGH FH; (B) FH I and FH II; and (C)
COMBO II (on-treatment analysis). Values on charts above data points indicate percentage reduction from baseline. Values below the x-axes indicate the
number of patients with data available at each time point. Missing data were accounted for by means of multiple imputation. ALI ¼ alirocumab; EZE ¼
ezetimibe; Lp(a) ¼ lipoprotein(a); PBO ¼ placebo; Q2W ¼ every 2 weeks; SE ¼ standard error.
Preventive Cardiology/Alirocumab Effect on Lipoprotein(a) 43In patients with HeFH from the FH I and FH II studies,
Lp(a) was reduced from baseline by 26.9% at week 24 with
alirocumab 75/150-mg Q2W versus 8.5% with placebo
(mean difference 18.4%; p <0.0001; ITT analysis).
Likewise, in patients with HeFH from LONG TERM andHIGH FH, Lp(a) decreased by 26.0% at week 24 in the
alirocumab 150-mg Q2W group and by 2.8% in the placebo
group (mean difference 23.3%; p <0.0001; ITT analysis).
Percentage Lp(a) reductions with alirocumab were
consistent regardless of baseline Lp(a) or LDL-C levels
Figure 3. Percentage change in Lp(a) from baseline to week 24 according to baseline Lp(a) levels (A) and (B) and baseline LDL-C levels (C and D; placebo-
controlled studies only; ITT analysis). Figures are Tukey boxplots: Central lines in boxes indicate median values, upper and lower regions of boxes indicate
upper and lower quartiles, respectively, and ends of the upper and lower lines extending from boxes indicate the lowest and highest values still within 1.5
interquartile ranges of the lower and upper quartiles. Interaction p values comparing baseline Lp(a) and LDL-C groups were all >0.05.
44 The American Journal of Cardiology (www.ajconline.org)(Figure 3). Greater percentage reductions in Lp(a) showed a
moderate-to-low correlation with greater percentage re-
ductions in LDL-C (Spearman’s correlation coefﬁcient:
0.307; Supplementary Figure 2). A moderate-to-low corre-
lation between percentage reduction in Lp(a) versus LDL-C
was also observed in patients with baseline Lp(a)  or
<50 mg/dl and in patients with and without HeFH
(Supplementary Figures 3 and 4). Similarly, there was a
signiﬁcant trend for greater Lp(a) percentage reductions and
lower achieved LDL-C levels (Supplementary Figure 5).
Analysis of results by absolute change in Lp(a) levels gave
similar results to the analysis by percentage change in Lp(a)
(Supplementary Figures 6 and 7).
There was no signiﬁcant difference in percentage Lp(a)
reductions according to race (white vs other racial and
ethnic groups); however, there were relatively few patients
of other racial and ethnic origin compared with white pa-
tients (469 of 4,446; 10.5%; Supplementary Figure 8). There
was no difference in percentage Lp(a) reduction either be-
tween men and women or by baseline aspirin use
(Supplementary Figure 9).
Overall rates of treatment-emergent adverse events in the
trials included in this analysiswere similar between alirocumab
and control patients (Supplementary Table 8). Of treatment-
emergent adverse events occurring in 5% patients, those
occurring in a higher proportion (0.5%) of alirocumab-
treated patients versus placebo were nasopharyngitis,injection-site reaction, and inﬂuenza; in trials versus ezetimibe,
these were upper respiratory tract infection, accidental over-
dose, and headache (Supplementary Table 8).
Discussion
Long-term prospective epidemiological studies reveal a
continuous association between increasing Lp(a) levels and
risk of coronary heart disease and stroke, independent of
LDL-C or nonehigh-density lipoprotein cholesterol
levels.11 Elevated Lp(a) levels are also associated with
increased risk of aortic valve stenosis.12 European (Euro-
pean Society of Cardiology/European Atherosclerosis So-
ciety) and US (National Lipid Association) guidelines state
that Lp(a) screening can be considered in high-risk patients
such as those with FH.13,14 In terms of treatment recom-
mendations, statins have little effect on Lp(a), and other
currently available treatment options are limited.14,15 How-
ever, to date, there is no evidence from a controlled trial that
lowering Lp(a) levels reduce CV events.14e16
The ODYSSEY program included a broad population of
patients at high risk of atherosclerotic CV disease, who were
not at LDL-C goals despite treatment with maximally
tolerated statin in most studies. Patients had median Lp(a)
levels ranging from 15 to 29 mg/dl, and 33% of them dis-
played baseline levels of 50 mg/dl, a level considered to
put them at increased CV risk.14 Across all study pools,
Preventive Cardiology/Alirocumab Effect on Lipoprotein(a) 45alirocumab signiﬁcantly lowered Lp(a) and LDL-C from
baseline levels (by 23.3% to 29.1% and 45.6% to 60.4%,
respectively, at week 24), with reductions sustained for
78 weeks. Safety was comparable across alirocumab and
control groups.
No difference in effect was observed across subgroups
including race and gender. Certain segments of the popu-
lation are known to have higher levels of Lp(a); for
example, African-Americans and, to a lesser extent, patients
of Hispanic origin.14 However, our analysis was limited by
the relatively low proportion of participants of other racial
and ethnic origin (w10% overall) in the studies. Alir-
ocumab signiﬁcantly lowered Lp(a) levels in patients with
HeFH, with reductions maintained up to 78 weeks.
Although contentious, it has been suggested that patients
with FH who are already at high risk of developing coronary
heart disease may have particularly elevated levels of
Lp(a).17 In this pooled analysis, patients with HeFH had
slightly higher median baseline levels of Lp(a) compared
with the non-FH patients (26.0 vs 22.9 mg/dl).
In the current analysis, the percentage reductions in Lp(a)
were not dependent on baseline levels of Lp(a) or LDL-C. A
moderate-to-low correlation between greater percentage re-
ductions in LDL-C and Lp(a) was found, which was stronger
than that reported for the phase 2 analysis10 but which does
not account for all the variation observed. The exact mech-
anism(s) involved in the lowering of Lp(a) by alirocumab is
still unclear and requires further investigation. Alirocumab is
considered to reduce LDL-C by preventing PCSK9-mediated
LDL receptor degradation, thereby increasing the number of
LDL receptors available to remove LDL-C from the circu-
lation.18 Statins also reduce LDL-C by increasing the number
of LDL receptors, but most studies have shown little effect of
these agents on Lp(a), suggesting that Lp(a) is not cleared
through the LDL receptor. It has been proposed that the LDL
receptor may become an important route for Lp(a) catabolism
following administration of a PCSK9 antibody, owing to a
supraphysiological increase in the number of LDL receptors
combined with the very low level of LDL-apolipoprotein
(apo) B.19 However, recent data strongly suggest a contri-
bution of non-LDL receptoremediated mechanisms in Lp(a)
clearance. It was previously reported that 2 homozygous FH
patients carrying null variants and no functioning LDL re-
ceptors showed signiﬁcant reductions in Lp(a) but no change
in LDL-C after treatment with evolocumab.20 NoneLDL-
receptor mechanisms for Lp(a) clearance are supported by
recent in vitro studies, suggesting a role for sortilin (a type 1
sorting receptor) in both Lp(a) internalization by hepatocytes
and apo(a) secretion.21,22
Statin treatment is known to increase PCSK9 levels,23,24
and in the present analysis, we found a correlation between
higher baseline Lp(a) and PCSK9 levels, and furthermore,
baseline Lp(a) and PCSK9 levels were lower in studies
performed without versus with statin. However, interpreta-
tion of this is limited because PCSK9 data were only
available for one of the studies performed without statin
(MONO), in which patients were at moderate CV risk9;
other factors may be responsible for the difference in
baseline Lp(a) levels between groups.
The consistent reductions in Lp(a) observed across the
ODYSSEY studies expand the previous data set fromalirocumab phase 2 studies, both in numbers of patients
studied and demonstration of maintenance of effect up to
104 weeks,10 suggesting that PCSK9 inhibition with alir-
ocumab not only effectively lowers LDL-C but also has a
substantial, sustained effect on Lp(a). Reductions in Lp(a)
reported for evolocumab, another PCSK9 inhibitor, were
broadly consistent with those observed with alirocumab.25
Long-term clinical beneﬁt of alirocumab treatment on the
incidence of major CV events is being assessed in the
ODYSSEY OUTCOMES clinical study (ClinicalTrials.gov
identiﬁer: NCT01663402), and results may provide further
insight into the impact of alirocumab-induced reductions in
LDL-C and Lp(a) on CV risk. Furthermore, speciﬁc studies
are underway or completed in nonwhite populations
(NCT02289963; NCT02107898; NCT0258450426).Acknowledgment: Editorial contributions were provided
by Diane Brisson, PhD, CCRP, Community Genetic Med-
icine Center, Université de Montréal, and ECOGENE-21
clinical research center, Chicoutimi, Québec, Canada. The
following people from the study sponsors reviewed this
manuscript: Regeneron: Carol Hudson, BPharm, Robert
Pordy, MD, and Jaman Maroni, MD; Sanoﬁ: L. Veronica
Lee, MD, Michael Howard, MBA, and Tu Nguyen, MD.
Medical writing support was provided by Rob Campbell,
PhD, of Prime Medica Ltd., Knutsford, Cheshire, UK,
funded by Sanoﬁ and Regeneron Pharmaceuticals, Inc.
Responsibility for all opinions, conclusions, and data
interpretation lies with the authors.Disclosures
Dr. Gaudet is a consultant/advisory panel member for
Sanoﬁ, Regeneron, Amgen, Novartis, Ionis, Catabasis,
Aegerion, Omthera, Uniqure, Chiesi, Gemphire, and
CymaBay. Dr. Wattshas received research funding from
Amgen and Sanoﬁ, has participated in a speakers’ bureau
for Merck, and is a consultant/advisory panel member for
Amgen and Sanoﬁ. Dr. Robinson has received research
grants from Amarin, Amgen, AstraZeneca, Eli Lilly, Eisai,
GlaxoSmithKline, Merck, Pﬁzer, Sanoﬁ/Regeneron, and
Takeda, consultant/advisory board member for Akcea/Ionis,
Amgen, Eli Lilly, Esperion, Merck, Pﬁzer, and Sanoﬁ/
Regeneron. Drs. Minini and Edelberg are stockholders in
and employees of Sanoﬁ. Drs. Sasiela and Louie are em-
ployees of and stockholders in Regeneron. Dr. Raal’s
institution has received research grants from Amgen and
Sanoﬁ/Regeneron, and he has received fees for consultant/
advisory boards/lectures and travel expenses from Amgen,
Sanoﬁ, Merck, Pﬁzer, and AstraZeneca.Supplementary Data
Supplementary data related with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.amjcard.
2016.09.010.
1. Bays H, Gaudet D, Weiss R, Ruiz JL, Watts GF, Gouni-Berthold I,
Robinson J, Zhao J, Hanotin C, Donahue S. Alirocumab as add-on to
atorvastatin versus other lipid treatment strategies: ODYSSEY
46 The American Journal of Cardiology (www.ajconline.org)OPTIONS I randomized trial. J Clin Endocrinol Metab 2015;100:
3140e3148.
2. Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R,
Chaudhari U, Colhoun HM. Efﬁcacy and safety of alirocumab in high
cardiovascular risk patients with inadequately controlled hyper-
cholesterolaemia on maximally tolerated doses of statins: the ODYSSEY
COMBO II randomized controlled trial.EurHeart J 2015;36:1186e1194.
3. Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E,
Colhoun HM, Du Y, Hanotin C, Donahue S. Efﬁcacy and safety of
adding alirocumab to rosuvastatin versus adding ezetimibe or doubling
the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY
OPTIONS II randomized trial. Atherosclerosis 2016;244:138e146.
4. Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R,
Dufour R, Blom D, Civeira F, Krempf M, Lorenzato C, Zhao J,
Pordy R, Baccara-Dinet MT, Gipe DA, Geiger MJ, Farnier M.
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment
in 735 patients with heterozygous familial hypercholesterolaemia. Eur
Heart J 2015;36:2996e3003.
5. Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT,
Lorenzato C, Pordy R, Stroes E. Efﬁcacy and safety of alirocumab in
patients with heterozygous familial hypercholesterolemia and LDL-C
of 160 mg/dL or higher. Cardiovasc Drugs Ther 2016;30:473e483.
6. Kereiakes DJ, Robinson JG, Cannon CP, Lorenzato C, Pordy R,
Chaudhari U, Colhoun HM. Efﬁcacy and safety of the proprotein
convertase subtilisin/kexin type 9 inhibitor alirocumab among high
cardiovascular risk patients on maximally tolerated statin therapy: the
ODYSSEY COMBO I study. Am Heart J 2015;169:906e915.e913.
7. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J,
Zieve F, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT,
Du Y, Gipe D. Efﬁcacy and safety of alirocumab versus ezetimibe in
statin-intolerant patients, with a statin-re-challenge arm: the ODYSSEY
ALTERNATIVE randomized trial. J Clin Lipidol 2015;9:758e769.
8. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M,
Stroes ES, Langslet G, Raal FJ, El SM, Koren MJ, Lepor NE,
Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ. Efﬁcacy and safety
of alirocumab in reducing lipids and cardiovascular events. N Engl J
Med 2015;372:1489e1499.
9. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM,
Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy
with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with
hypercholesterolemia: results of a 24 week, double-blind, randomized
Phase 3 trial. Int J Cardiol 2014;176:55e61.
10. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D,
Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a
monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lip-
oprotein(a) concentrations (a pooled analysis of 150 mg every two
weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711e715.
11. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, White IR,
Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a)
concentration and the risk of coronary heart disease, stroke, and
nonvascular mortality. JAMA 2009;302:412e423.
12. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lip-
oprotein(a) and risk of aortic valve stenosis in the general population.
J Am Coll Cardiol 2014;63:470e477.
13. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH,
McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP,
Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1efull report. J Clin Lip-
idol 2015;9:129e169.
14. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F,
Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS,
Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L,
Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A. Lip-
oprotein(a) as a cardiovascular risk factor: current status. Eur Heart J
2010;31:2844e2853.
15. Bos S, Yayha R, van Lennep JE. Latest developments in the treatment
of lipoprotein (a). Curr Opin Lipidol 2014;25:452e460.
16. Kasssner U, Schlabs T, Rosada A, Steinhagen-Thiessen E. Lip-
oprotein(a)eAn independent causal risk factor for cardiovascular dis-
ease and current therapeutic options. Atheroscler Suppl 2015;18:
263e267.
17. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN,
Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ,
Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG,
Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E,
Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF,
Stroes E, Taskinen MR, Tybjaerg-Hansen A. Familial hyper-
cholesterolaemia is underdiagnosed and undertreated in the general
population: guidance for clinicians to prevent coronary heart disease:
consensus statement of the European Atherosclerosis Society. Eur
Heart J 2013;34:3478ae3490a.
18. Seidah NG, Prat A. The biology and therapeutic targeting of the pro-
protein convertases. Nat Rev Drug Discov 2012;11:367e383.
19. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG,
Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein
convertase subtilisin/kexin type 9 through the low density lipoprotein
receptor. J Biol Chem 2015;290:11649e11662.
20. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect
of the proprotein convertase subtilisin/kexin 9 monoclonal antibody,
AMG 145, in homozygous familial hypercholesterolemia. Circulation
2013;128:2113e2120.
21. Koschinsky M, Gemin M, Scipione C, Boffa M, Seidah N,
Romagnuolo R. Evaluating the roles of PCSK9 and speciﬁc receptors
in lipoprotein(a) catabolism. J Clin Lipidol 2016;10:720e721.
22. Kurt B, SouﬁM, Sattler A, Schaefer JR. Lipoprotein(a)-clinical aspects
and future challenges. Clin Res Cardiol Suppl 2015;10:26e32.
23. Guo YL, Zhang W, Li JJ. PCSK9 and lipid lowering drugs. Clin Chim
Acta 2014;437:66e71.
24. Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ. Effects of
niacin, statin, and fenoﬁbrate on circulating proprotein convertase
subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J
Cardiol 2015;115:178e182.
25. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG,
Honarpour N, Lira A, Xue A, Chiruvolu P, Jackson S, Di M, Peach M,
Somaratne R, Wasserman SM, Scott R, Stein EA. PCSK9 inhibition-
mediated reduction in Lp(a) with evolocumab: an analysis of 10 clin-
ical trials and the LDL receptor’s role. J Lipid Res 2016;57:
1086e1096.
26. Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T,
Takagi Y, Uno K, Baccara-Dinet MT, Nohara A. Efﬁcacy and safety of
alirocumab in Japanese patients with heterozygous familial hypercho-
lesterolemia or at high cardiovascular risk with hypercholesterolemia
not adequately controlled with statins- ODYSSEY Japan randomized
controlled trial. Circ J 2016;80:1980e1987.
